Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Operating Leases (2019 - 2025)

Historic Operating Leases for Perspective Therapeutics (CATX) over the last 7 years, with Q3 2025 value amounting to $971000.0.

  • Perspective Therapeutics' Operating Leases fell 4206.44% to $971000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $971000.0, marking a year-over-year decrease of 4206.44%. This contributed to the annual value of $1.4 million for FY2024, which is 8307.69% up from last year.
  • Per Perspective Therapeutics' latest filing, its Operating Leases stood at $971000.0 for Q3 2025, which was down 4206.44% from $1.1 million recorded in Q2 2025.
  • Perspective Therapeutics' Operating Leases' 5-year high stood at $1.7 million during Q3 2024, with a 5-year trough of $256000.0 in Q2 2022.
  • Its 5-year average for Operating Leases is $892611.1, with a median of $792500.0 in 2023.
  • In the last 5 years, Perspective Therapeutics' Operating Leases plummeted by 5114.5% in 2022 and then skyrocketed by 24257.64% in 2023.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Operating Leases stood at $652000.0 in 2021, then dropped by 29.75% to $458000.0 in 2022, then skyrocketed by 70.31% to $780000.0 in 2023, then skyrocketed by 83.08% to $1.4 million in 2024, then crashed by 32.0% to $971000.0 in 2025.
  • Its last three reported values are $971000.0 in Q3 2025, $1.1 million for Q2 2025, and $1.2 million during Q1 2025.